Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.
Also called NCT01068678
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 460 participants
- Sponsor
- Registry
-
NCT01068678 -
2009-011398-33
-
- Other papers using this trial's data
- Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Israel, Puerto Rico, Slovakia, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01068678. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2015-12-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01068678- Content hash
990e3ba08cd5b0e477f4ea99050cfeff9bbf9966bf25919e794e6200740f674b